JOURNAVX is the first and only approved non-opioid oral pain signal inhibitor and the first new class of pain medicine approved in more than 20 years -- ...

Vertex Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVXtm (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal ...

Dry January is pretty much over and if you've made it this far then you have probably felt the benefits. Many will have noticed improved sleep, glowing skin and slimmer waistlines.

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, will ...